vidarabine has been researched along with Waldenstrom Macroglobulinemia in 86 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (17.44) | 18.2507 |
| 2000's | 43 (50.00) | 29.6817 |
| 2010's | 27 (31.40) | 24.3611 |
| 2020's | 1 (1.16) | 2.80 |
| Authors | Studies |
|---|---|
| Burningham, Z; Chien, HC; Halwani, AS; Li, CY; Morreall, D; Passey, DG; Patil, V; Rasmussen, KM; Sauer, BC; Yong, CM | 1 |
| Tian, C; Yu, Y; Zhang, Y | 1 |
| Bakala, J; Declercq, H; Delette, C; Drumez, E; Duhamel, A; Guidez, S; Hivert, B; Labreuche, J; Marolleau, JP; Morel, P; Protin, C; Verlay, M; Ysebaert, L | 1 |
| Baldini, L; Barate', C; Benevolo, G; Frustaci, AM; Gini, G; Goldaniga, MC; Luraschi, A; Morra, E; Motta, M; Nichelatti, M; Pioltelli, P; Ricci, F; Tedeschi, A; Varettoni, M; Vismara, E; Vitolo, U | 1 |
| Choquet, S; Leblond, V; Nguyen, S; Souchet-Compain, L | 1 |
| Adam, Z; Krejčí, M; Pour, L; Ševčíková, E | 1 |
| Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP | 1 |
| Fujieda, A; Imai, H; Katayama, N; Masuya, M; Miyazami, K; Nagaharu, K; Sugimoto, Y; Tamura, A; Umino, A; Yamaguchi, M | 1 |
| Groeneveld, ON; Kersten, MJ; Kraan, W; Linn, C; Minnema, MC; Pals, ST; Vos, JM | 1 |
| Treon, SP | 1 |
| Boubaya, M; Choquet, S; Delmer, A; Dupuis, J; Le Gouill, S; Leblond, V; Levy, V; Ouzegdouh, M; Pégourié-Bandelier, B; Souchet, L; Tamburini, J; Tournilhac, O; Vargaftig, J | 1 |
| Dimopoulos, MA; Fotiou, D; Gavriatopoulou, M; Kastritis, E; Kyrtsonis, MC; Migkou, M; Mpakiri, M; Roussou, M; Tasidou, A; Terpos, E; Vassilakopoulos, TP | 1 |
| Azlin, I; Fadilah, SA; Muhaya, M | 1 |
| Bhandari, S; Cranfield, T; Simon, G; Walker, M | 1 |
| Branagan, AR; Emmanouilides, C; Frankel, SR; Gregory, SA; Ioakimidis, L; Kimby, E; Lister, A; Matous, J; Morel, P; Patterson, CJ; Soumerai, JD; Treon, SP; Turnbull, B; Wasi, P | 1 |
| Adamia, S; Ciccarelli, BT; Ghobrial, IM; Hatjiharissi, E; Hunter, ZR; Ioakimidis, L; Leleu, X; Manning, R; Moreau, AS; Patterson, CJ; Roccaro, A; Sacco, A; Soumerai, J; Treon, SP | 1 |
| Tan, J; Wu, T; Yang, K | 1 |
| Ashcroft, AJ; Moreton, P; Owen, RG; Rawstron, AC; Varghese, AM | 1 |
| Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kastritis, E; Migkou, M; Roussou, M; Tassidou, A; Terpos, E | 1 |
| Alamos, SM; Greco, A; Morra, E; Ricci, F; Tedeschi, A | 1 |
| Assanasen, T; Polprasert, C; Prayongratana, K; Wongchitrat, C | 1 |
| Harnalikar, M; Kharkar, V; Khopkar, U; Pande, S | 1 |
| Anderson, KC; Ghobrial, IM; Rourke, M | 1 |
| Gertz, MA | 2 |
| Peinert, S; Seymour, JF | 1 |
| Bouscary, D; Dreyfus, F; Park, S; Pilorge, S; Tamburini, J | 1 |
| Januszewicz, EH; Peinert, S; Prince, HM; Scarlett, J; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM | 1 |
| Hivert, B; Leblond, V; Morel, P; Tamburini, J; Tournilhac, O; Vekhoff, A | 1 |
| Haller, NA; Lee, B; Novak, R; Robertson, S; Smith, RS; Tanphaichitr, N | 1 |
| Battista, ML; Benevolo, G; Lazzarino, M; Meneghini, V; Morra, E; Nichelatti, M; Pioltelli, P; Ricci, F; Sacchi, S; Tedeschi, A; Varettoni, M; Visco, C; Vitolo, U; Zaja, F; Zinzani, PL | 1 |
| Han, W; Wei, Z; Yanxia, Y; Ying, X; Yuhua, J | 1 |
| Mitra, S; Pyatt, N | 1 |
| Arima, H; Imai, Y; Inoue, D; Kiuchi, M; Maruoka, H; Matsushita, A; Mori, M; Nagano, S; Oita, T; Tabata, S; Takahashi, T; Takiuchi, Y; Yamashiro, A | 1 |
| Fabiano, AJ; Fenstermaker, RA; Qiu, J; Rigual, D | 1 |
| Andrieux, J; Baranger, L; Barin, C; Bilhou-Nabera, C; Blons, H; Callet-Bauchu, E; Chapiro, E; Chevret, S; Chiesa, J; Daudignon, A; Eclache, V; Gachard, N; Grelier, A; Henry, C; Lambert, J; Leblondon, V; Lejeune, J; Luquet, I; Merle-Beral, H; Mossafa, H; Mould, S; Mozziconacci, MJ; Mugneret, F; Nguyen-Khac, F; Owen, R; Penther, D; Struski, S; Terre, C; Veronese, L | 1 |
| Hanzis, C; Hunter, ZR; Ioakimidis, L; Manning, RJ; Patterson, CJ; Sheehy, P; Treon, SP; Tripsas, C; Turnbull, B | 1 |
| Chevret, S; Choquet, S; Copplestone, A; Dartigeas, C; Dilhuydy, MS; Ewings, M; Johnson, S; Leblond, V; Lejeune, J; Malphettes, M; Morel, P; Nguyen-Khac, F; Owen, RG; Patmore, RD; Pratt, G; Royer, B; Rule, S; Seymour, JF; Tournilhac, O; Willoughby, S; Wright, D | 1 |
| Herrera, GA; Isaac, J | 1 |
| Alinari, L; Baccarani, M; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Barlogie, B; Crowley, JJ; Dhodapkar, MV; Gertz, MA; Jacobson, JL | 1 |
| Choquet, S; Leblond, V | 1 |
| Anagnostopoulos, N; Dimopoulos, MA; Efstathiou, E; Gika, D; Grigoraki, V; Hamilos, G; Matsouka, C; Mitsibounas, D; Papadimitriou, C; Siapkaras, I | 1 |
| Carta, F; Dore, F; Dore, S; Pinna, A; Salis, A | 1 |
| Johnson, SA | 1 |
| Käser, L; Kolyvanos Naumann, U; Vetter, W | 1 |
| Creamer, D; Devereux, S; Mufti, G; Perera, GK; Salisbury, J | 1 |
| Catovsky, D; Del Giudice, I; Matutes, E; Osuji, N; Parry-Jones, N; Swansbury, J | 1 |
| Chevret, S; Leblond, V; Lévy, V; Morel, P; Porcher, R; Wattel, E | 1 |
| Jaeger, U; Johnson, SA; Leblond, V; Levy, V; Oscier, DG; Owen, RG; Seymour, JF | 1 |
| Amin, CJ; Rabinowitz, I | 1 |
| Chaleteix, C; Choquet, S; Christian, B; Delmer, A; Dreyfus, F; Fermand, JP; Grange, MJ; Leblond, V; Lévy, V; Morel, P; Stalniewicz, L; Tamburini, J | 1 |
| Cho, HS; Chun, SH; Hyun, MS; Kim, KO; Kim, MK; Lee, KH; Shin, SJ | 1 |
| Januszewicz, EH; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM | 1 |
| Birchall, J; Johnson, SA; Luckie, C; Oscier, DG; Owen, RG | 1 |
| Carney, D; Januszewicz, EH; Lin, KI; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, M | 1 |
| Buzyn, A; Candon, S; Casadevall, N; Hummel, A; Ittah, M; Lavie, F; Louache, F; Mariette, X; Soumelis, V; Terrier, B; Tourneur, L | 1 |
| Cassells, R; Cheow, HK; Giles, A; Lim, Z; Mir, N | 1 |
| Anevlavis, E; Christopoulos, C; Fortis, A; Tassidou, A | 1 |
| Cho, HS; Hyun, MS; Kim, HD; Kim, MK; Lee, KH; Shin, KC | 1 |
| Anderson, KC; Ciccarelli, B; Dammacco, F; Ghobrial, IM; Hatjiharissi, E; Jia, X; Leleu, X; Moreau, AS; Ngo, HT; Patterson, CJ; Roccaro, AM; Russo, D; Sacco, A; Treon, SP; Vacca, A; Xu, L | 1 |
| Forsberg, K; Lazarevic, VLj; Liljeholm, M; Söderberg, S; Wahlin, A | 1 |
| Hiddemann, W; Pott-Hoeck, C | 1 |
| Cabanillas, F; Dimopoulos, M; Gandhi, V; Gregoire, V; Kantarjian, H; Keating, MJ; Li, YY; McLaughlin, P; O'Brien, S; Robertson, LE | 1 |
| Aitini, E; Bendandi, M; Gherlinzoni, F; Salvucci, M; Tura, S; Zaccaria, A; Zinzani, PL | 1 |
| Keating, MJ; O'Brien, S; Plunkett, W; Robertson, LE; Wright, SJ | 1 |
| Alexanian, R; Dimopoulos, MA; Estey, EE; Kantarjian, H; Keating, MJ; O'Brien, S | 1 |
| Bosly, A; Brousset, P; Delannoy, A; Pris, J; Riga-Huguet, F; Schlaifer, D | 1 |
| Cabanillas, F; Gandhi, V; Gregoire, V; Keating, MJ; McLaughlin, P; O'Brien, S; Plunkett, W; Robertson, LE; Yang, L | 1 |
| Hałaburda, K; Hellmann, A | 1 |
| Alexanian, R; Barlogie, B; Delasalle, K; Dimopoulos, MA; Kantarjian, H; Keating, MJ; O'Brien, S; Pierce, S | 1 |
| Björkholm, M; Celsing, F; Runarsson, G; Waldenström, J | 1 |
| Kantarjian, H; Keating, MJ; O'Brien, S | 1 |
| Piro, LD; Saven, A | 1 |
| Aitini, E; Costa, P; Forghieri, ME; Lazzarini, L; Luzzati, R; Nicolato, A; Perboni, G; Scalzini, A; Zinzani, PL | 1 |
| Ben-Othman, T; Caspard, H; Clauvel, JP; Deconinck, E; Delgado, MA; Delmer, A; Duboisset, P; Entezam, S; Fort, N; Guibon, O; Harousseau, JL; Hermine, O; Leblond, V; Maloisel, F; Mariette, X; Merlet, M; Morel, P; Taksin, AL; Yakoub-Agha, I | 1 |
| del Potro Gómez, E; Morales Sanz, D | 1 |
| Campos, F; Dufour, P; Giron, C; Maloisel, F | 1 |
| Chee, YL; Culligan, DJ; Kurtz, JB; Molyneaux, P; Olson, JA; Watson, HG | 1 |
| Chott, A; Geissler, K; Gisslinger, H; Jäger, U; Knöbl, P; Lechner, K; Schwarzinger, I; Thalhammer-Scherrer, R | 1 |
| Barlogie, B; Crowley, JJ; Dhodapkar, MV; Gertz, MA; Jacobson, JL; Kyle, RA; Rivkin, SE; Roodman, GD; Shurafa, M; Tuscano, JM | 1 |
| Cazin, B; Chevret, S; Fermand, JP; Guibon, O; Harousseau, JL; Leblond, V; Lévy, V; Maloisel, F; Porcher, R; Remenieras, L | 1 |
| Owen, RG | 1 |
| Cazin, B; Deconinck, E; Desablens, B; Fermand, JP; Gardembas, M; Guibon, O; Guilhot, F; Harousseau, JL; Leblond, V; Lévy, V; Maloisel, F; Marit, G; Philippe, G; Porcher, R; Remenieras, L; Stamatoullas, A | 1 |
| Halaburda, K; Hellmann, A; Lewandowski, K | 1 |
| Barlogie, B; Desikan, KR; Dhodapkar, MV | 1 |
20 review(s) available for vidarabine and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
[Therapy of Waldenström´s macroglobulinaemia in the year 2014].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Immunologic Factors; Immunosuppressive Agents; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2014 |
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2014 |
Alkylating agents for Waldenstrom's macroglobulinaemia.
Topics: Alkylating Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Prednisone; Randomized Controlled Trials as Topic; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Rituximab-based treatments in Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Doxorubicin; Humans; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Fludarabine-based combination therapies for Waldenström's macroglobulinemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Rituximab; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
Waldenström's macroglobulinemia: a review of therapy.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cladribine; Hematopoietic Stem Cell Transplantation; Humans; Plasma Exchange; Rituximab; Splenectomy; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2002 |
Fludarabine in Waldenstrom's macroglobulinemia.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Vidarabine; Waldenstrom Macroglobulinemia | 2003 |
Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2004 |
[Waldenstrom macroglobulinemia].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Blood Transfusion; Chlorambucil; Diagnosis, Differential; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Plasmapheresis; Prednisone; Prognosis; Recurrence; Rituximab; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2004 |
Guidelines on the management of Waldenström macroglobulinaemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cladribine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Plasma Exchange; Prognosis; Rituximab; Stem Cell Transplantation; Thalidomide; Vidarabine; Waldenstrom Macroglobulinemia | 2006 |
Fludarabine in the management of malignant lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Incidence; Lymphoma; Lymphoma, Non-Hodgkin; Mycoses; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
The expanding role of fludarabine in hematologic malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
The role of fludarabine in hematological malignancies.
Topics: Adult; Aged; Bone Marrow Diseases; Clinical Trials, Phase I as Topic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mycosis Fungoides; Remission Induction; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Molecular Structure; Multicenter Studies as Topic; Radiation-Sensitizing Agents; Remission Induction; Tumor Cells, Cultured; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia.
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Purine Nucleosides; Vidarabine; Waldenstrom Macroglobulinemia | 1996 |
2-Chlorodeoxyadenosine treatment of lymphoma.
Topics: Adenosine Deaminase; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cladribine; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell, Cutaneous; Pentostatin; Vidarabine; Waldenstrom Macroglobulinemia | 1996 |
[Multiple myeloma and other plasma cell dyscrasias].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Child; Diagnosis, Differential; Heavy Chain Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Prognosis; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 1999 |
Treatment options in Waldenström's macroglobulinaemia: the role of the purine analogues.
Topics: Alkylating Agents; Antimetabolites; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Resistance; Drug Therapy, Combination; Guidelines as Topic; Humans; Middle Aged; Pentostatin; Plasmapheresis; Purine Nucleosides; Quality of Life; Vidarabine; Waldenstrom Macroglobulinemia | 2001 |
Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; beta 2-Microglobulin; Chlorambucil; Cladribine; Clinical Trials as Topic; Combined Modality Therapy; Humans; Interferon-alpha; Neoplasm Recurrence, Local; Plasmapheresis; Rituximab; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia | 2000 |
14 trial(s) available for vidarabine and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Humans; Recurrence; Retreatment; Survival Analysis; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2017 |
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Neutropenia; Pneumonia; Prospective Studies; Rituximab; Survival Rate; Thrombocytopenia; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Immunosuppression Therapy; Male; Middle Aged; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 4; Chromosomes, Human, Pair 6; Female; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Karyotype; Male; Middle Aged; Prognosis; Prospective Studies; Trisomy; Vidarabine; Waldenstrom Macroglobulinemia | 2013 |
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Proportional Hazards Models; Vidarabine; Waldenstrom Macroglobulinemia | 2013 |
Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).
Topics: Antineoplastic Agents; Follow-Up Studies; Humans; Prognosis; Proportional Hazards Models; Remission Induction; Survival Analysis; Vidarabine; Waldenstrom Macroglobulinemia | 2003 |
Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide.
Topics: Aged; Aged, 80 and over; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Survival Analysis; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2003 |
Advanced Waldenström's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis.
Topics: Aged; Antineoplastic Agents; Cohort Studies; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Male; Middle Aged; Multivariate Analysis; Prednisone; Prognosis; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Female; Humans; Lymphoma; Male; Middle Aged; Prospective Studies; Splenic Neoplasms; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Fludarabine treatment in resistant Waldenstrom's macroglobulinemia.
Topics: Aged; Female; Follow-Up Studies; Humans; Male; Middle Aged; Vidarabine; Waldenstrom Macroglobulinemia | 1995 |
Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Humans; Middle Aged; Remission Induction; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia | 1993 |
Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).
Topics: Age Factors; Aged; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers; Cohort Studies; Disease-Free Survival; Female; Hemoglobins; Humans; Immunoglobulin M; Male; Models, Biological; Multivariate Analysis; Odds Ratio; Prognosis; Prospective Studies; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia | 2001 |
Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality-adjusted survival analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Health Status Indicators; Humans; Prednisone; Quality of Life; Retrospective Studies; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia | 2001 |
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance; Female; Humans; Male; Middle Aged; Mouth Mucosa; Prednisone; Recurrence; Salvage Therapy; Stomatitis; Survival Analysis; Therapeutic Equivalency; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2001 |
52 other study(ies) available for vidarabine and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Chlorambucil; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Kaplan-Meier Estimate; Piperidines; Prednisone; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Veterans; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Waldenström macroglobulinaemia terminating in acute lymphoblastic leukaemia after treatment with fludarabine.
Topics: Aged; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine; Waldenstrom Macroglobulinemia | 2019 |
Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Female; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Risk Factors; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2018 |
Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Male; Middle Aged; Retrospective Studies; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2013 |
Fludarabine in Waldenstrom's macroglobulinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Disease-Free Survival; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2013 |
[Successful treatment of Bing-Neel syndrome using combination therapy with fludarabine and rituximab].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Bone Marrow; Drug Combinations; Humans; Magnetic Resonance Imaging; Male; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2014 |
Effective treatment of Bing-Neel Syndrome with oral fludarabine: a case series of four consecutive patients.
Topics: Administration, Oral; Adult; Aged; Central Nervous System Diseases; Female; Humans; Male; Middle Aged; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2016 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosphamide; Female; Humans; Male; Middle Aged; Pancytopenia; Retrospective Studies; Rituximab; Survival Rate; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2016 |
Irreversible visual loss and optic nerve dysfunction associated with central retinal vein occlusion in Waldenstrom Macroglobulinemia.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Male; Optic Nerve; Optic Nerve Diseases; Plasmapheresis; Prognosis; Retinal Vein; Risk Factors; Rituximab; Vidarabine; Vision, Low; Visual Acuity; Waldenstrom Macroglobulinemia | 2007 |
Images in haematology. Cerebral nocardiosis in a patient with lymphoplasmacytic lymphoma treated with fludarabine.
Topics: Aged, 80 and over; Antineoplastic Agents; Central Nervous System Bacterial Infections; Humans; Male; Nocardia Infections; Opportunistic Infections; Tomography, X-Ray Computed; Vidarabine; Waldenstrom Macroglobulinemia | 2008 |
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Chlorambucil; Cladribine; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Nucleosides; Retrospective Studies; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Assessment of bone marrow response in Waldenström's macroglobulinemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Female; Flow Cytometry; Humans; Immunoglobulin M; Immunohistochemistry; Male; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Lymphoplasmacytic lymphoma with IgA hypergammaglobulinemia and liver involvement.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antirheumatic Agents; Cyclophosphamide; Female; Humans; Hypergammaglobulinemia; Immunoglobulin A; Immunologic Factors; Liver Diseases; Rituximab; Thailand; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Keratotic vascular papules over the feet: a case of Waldenström's macroglobulinaemia-associated cutaneous macroglobulinosis.
Topics: Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Diagnosis, Differential; Fluorescent Antibody Technique, Direct; Foot Diseases; Humans; Immunoglobulin M; Keratosis; Male; Middle Aged; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
What's new in Waldenström macroglobulinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Rituximab; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Rituximab; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Disorders; Cyclophosphamide; Humans; Male; Middle Aged; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Humans; International Classification of Diseases; Male; Middle Aged; Prognosis; Recurrence; Rituximab; Time Factors; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2011 |
Waldenström's macroglobulinemia and nephrotic syndrome with membranous nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Glomerulonephritis, Membranous; Humans; Immunoglobulin lambda-Chains; Immunoglobulin M; Male; Nephrotic Syndrome; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2011 |
Splenic re-irradiation for waldenstrőm's macroglobulinemia.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Radiotherapy, Conformal; Spleen; Thalidomide; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Cytomegalovirus oesophagitis following treatment with fludarabine for refractory lymphoplasmacytic lymphoma.
Topics: Antineoplastic Agents; Antiviral Agents; Biopsy; Cytomegalovirus Infections; Diagnosis, Differential; Endoscopy, Digestive System; Esophagitis; Ganciclovir; Humans; Immunocompromised Host; Male; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed; Valganciclovir; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Successful treatment of γ-heavy-chain disease with rituximab and fludarabine.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Heavy Chain Disease; Humans; Lymphoma, B-Cell; Male; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Tumoral Bing-Neel Syndrome presenting as a cerebellar mass.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Brain Edema; Cerebellar Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Nervous System Diseases; Neurosurgical Procedures; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2013 |
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Disease Progression; Disease-Free Survival; Genetic Predisposition to Disease; Humans; Middle Aged; Pyrazines; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Cast nephropathy in a case of Waldenström's macroglobulinemia.
Topics: Aged; Biopsy; Female; Humans; Immunoglobulin A; Immunohistochemistry; Immunosuppressive Agents; Kidney Diseases; Kidney Glomerulus; Renal Dialysis; Vidarabine; Waldenstrom Macroglobulinemia | 2002 |
Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Case Management; Chlorambucil; Cladribine; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Immunoglobulin M; Male; Middle Aged; Mitoxantrone; Plasmapheresis; Prednisone; Rituximab; Severity of Illness Index; Thalidomide; Vidarabine; Vinblastine; Vincristine; Vinorelbine; Waldenstrom Macroglobulinemia | 2003 |
Bilateral optic disc swelling as the presenting sign of Waldenström's macroglobulinaemia.
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Optic Disk; Papilledema; Prednisone; Vidarabine; Waldenstrom Macroglobulinemia | 2003 |
PNP with Waldenström's macroglobulinaemia.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Drug Eruptions; Fatal Outcome; Humans; Male; Paraneoplastic Syndromes; Pemphigus; Skin Neoplasms; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Disease Progression; Female; Humans; Pleural Effusion; Recurrence; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Female; Hemoglobins; Humans; Immunoglobulin M; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 5; Drug Administration Schedule; Humans; Male; Monosomy; Myelodysplastic Syndromes; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Male; Middle Aged; Mitoxantrone; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2006 |
Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Cell Activating Factor; B-Lymphocytes; Bone Marrow; Cell Lineage; Cells, Cultured; Cyclophosphamide; Cytokines; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Lymphopoiesis; Middle Aged; Myelopoiesis; Neutropenia; Rituximab; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2007 |
Diffuse large B-cell lymphoma developing following treatment of Waldenstrom's macroglobulinaemia: spontaneous resolution upon cessation of fludarabine.
Topics: Aged; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2007 |
Extramedullary, extranodal lymphoplasmacytic lymphoma with macroglobulinemia: long-term complete remission with fludarabine.
Topics: Aged; Antineoplastic Agents; Humans; Lung Neoplasms; Male; Vidarabine; Waldenstrom Macroglobulinemia | 2008 |
Therapeutic experience of Bing-Neel Syndrome associated with Waldenstrom's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Brain; Central Nervous System Diseases; Cranial Irradiation; Female; Humans; Middle Aged; Rituximab; Syndrome; Vidarabine; Waldenstrom Macroglobulinemia | 2007 |
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Dexamethasone; Drug Evaluation, Preclinical; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukocytes; Oligonucleotide Array Sequence Analysis; Pyrazines; Resveratrol; Signal Transduction; Stilbenes; TCF Transcription Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2008 |
Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Hypertension, Pulmonary; Male; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2008 |
Secondary neoplasms in two patients treated with purine analogues.
Topics: Acute Disease; Aged; Cladribine; Female; Humans; Immunocompromised Host; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melanoma; Neoplasms, Second Primary; Skin Neoplasms; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Fludarabine therapy in a patient with progressive symptomatic Waldenström's macroglobulinemia.
Topics: Antineoplastic Agents; Female; Follow-Up Studies; Hemoglobins; Humans; Immunoglobulin M; Middle Aged; Remission Induction; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Fludarabine therapy in Waldenström's macroglobulinemia.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Middle Aged; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 1993 |
Successful intravenous immunoglobulin therapy for severe and persistent astrovirus gastroenteritis after fludarabine treatment in a patient with Waldenström's macroglobulinemia.
Topics: Aged; Gastroenteritis; Humans; Immunization, Passive; Immunocompromised Host; Immunoglobulins, Intravenous; Male; Mamastrovirus; Opportunistic Infections; Peptic Ulcer; Vidarabine; Virus Diseases; Waldenstrom Macroglobulinemia | 1995 |
Cryptococcal meningitis and intracranial tuberculoma in a patient with Waldenstrom's macroglobulinemia treated with fludarabine.
Topics: Antineoplastic Agents; Brain Diseases; Female; Humans; Immunosuppressive Agents; Meningitis, Cryptococcal; Middle Aged; Opportunistic Infections; Tuberculoma; Vidarabine; Waldenstrom Macroglobulinemia | 1998 |
Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.
Topics: Adult; Aged; Aged, 80 and over; Blood Cell Count; Drug Resistance; Humans; Immunoglobulin M; Immunosuppressive Agents; Middle Aged; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 1998 |
Second treatment with fludarabine in a Waldenström's macroglobulinemia patient.
Topics: Adult; CD4-CD8 Ratio; Humans; Immunosuppressive Agents; Male; Vidarabine; Waldenstrom Macroglobulinemia | 2000 |
Sight-threatening varicella zoster virus infection after fludarabine treatment.
Topics: Acyclovir; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Eye Infections, Viral; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Lymphoma, Follicular; Male; Middle Aged; Polymerase Chain Reaction; Retinal Necrosis Syndrome, Acute; Vidarabine; Waldenstrom Macroglobulinemia | 2000 |
Fludarabine therapy in Waldenström's macroglobulinemia.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Therapeutic Equivalency; Vidarabine; Waldenstrom Macroglobulinemia | 2000 |
Fludarabine therapy in Waldenström's macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine.
Topics: Aged; Cladribine; Drug Evaluation; Humans; Immunoglobulin M; Immunosuppressive Agents; Middle Aged; Remission Induction; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2002 |